Effect of BCG immunotherapy on cell-mediated cytotoxicity in bladder cancer patients following surgical treatment.
D000328:Adult; D000818:Animals; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000276:immunology / Q000628:therapy*; D003602:Cytotoxicity, Immunologic; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006801:Humans; D007167:Immunotherapy; D008214:Lymphocytes / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D011948:Receptors, Antigen, T-Cell / Q000276:immunology; D012756:Sheep / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000628:therapy*
D001500:BCG Vaccine; D011948:Receptors, Antigen, T-Cell